HIV Oligonucleotide Primers for Broad Variant Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for detecting and quantifying HIV presence and load are limited in their ability to capture a wide variety of variant HIV sequences due to the virus's heterogeneity and high mutation rate, particularly affecting the integrase gene, leading to reduced sensitivity and accuracy in the presence of mutations associated with drug resistance.
Innovation Solution
The development of specific oligonucleotide primers and probes, such as SEQ ID NOs 23-51 and 56-84, that can hybridize to a broad range of HIV nucleic acid sequences, including those with mutations in the integrase gene, enabling accurate detection and quantification of HIV across various variants.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If conventional detection methods are used, then the methods are simple to implement, but they fail to detect a sufficient breadth of HIV variants due to high mutation rates and genetic heterogeneity
Solution Approach 1:
The patent designs primers and probes with universal binding characteristics that can recognize and bind to multiple HIV variants simultaneously. The oligonucleotides are engineered to target conserved regions across different HIV subtypes and mutant strains, enabling a single detection system to function across diverse viral sequences without requiring variant-specific reagents
Solution Approach 2:
The patent optimizes specific parameters of the oligonucleotides including melting temperature (Tm), GC content, and sequence composition to ensure stable binding across mutated sequences. By adjusting these parameters, the detection system maintains sensitivity and specificity even when viral sequences diverge from reference strains
2Measurement precision
If detection methods target specific HIV sequences, then they achieve high detection sensitivity for known variants, but they fail to detect variants with mutations in target regions
Solution Approach 1:
The patent divides the HIV genome into multiple target regions and designs corresponding primer-probe sets for each region. By segmenting the detection approach across multiple genomic locations, the system ensures that if mutations occur in one region, other regions remain detectable, thereby maintaining both sensitivity and broad variant coverage
Solution Approach 2:
The patent uses degenerate primers and probes as intermediaries that can bind to multiple sequence variations. These oligonucleotides contain mixed base positions (degeneracy) that act as mediators, allowing them to hybridize to diverse viral sequences despite sequence variations, thus bridging the gap between specific detection and broad coverage
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These oligonucleotides enhance the sensitivity and accuracy of HIV detection and quantification, allowing for effective monitoring of HIV load and informing treatment adjustments, even in the presence of drug-resistant mutations.
Implementation Method 1
a pair of oligonucleotide primers including a forward oligonucleotide primer and a reverse oligonucleotide primer that upon hybridization to an HIV nucleic acid molecule flank an amplicon sequence
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention is based in part on the present inventors' appreciation that certain sequences within an HIV genome are more likely to successfully detect HIV across a breadth of HIV variants. The ability to detect and/or quantify the presence and/or load of HIV in a subject is important to, among other things, the diagnosis and treatment of infected individuals. The present invention is based, in part, on the discovery of oligonucleotide reagents that detectably amplify sequences from a greater breadth of HIV samples than certain prior reagents and/or that generate amplicons from HIV genomes from which certain prior reagents would not have generated amplicons. Oligonucleotide reagents as described herein provide unexpected benefits in the detection and/or quantification of the presence and/or load of HIV in a subject, and thereby in the diagnosis and treatment of HIV.